Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Dermatologic 2Head & Neck 1CNS 1

Conditions

Melanoma 791Carcinoma, Non-Small-Cell Lung 171Skin Neoplasms 154Neoplasms 107Neoplasm Metastasis 100Colorectal Neoplasms 96Carcinoma, Renal Cell 96Uveal Melanoma 92Breast Neoplasms 88Squamous Cell Carcinoma of Head and Neck 85Carcinoma, Basal Cell 85Lung Neoplasms 80Ovarian Neoplasms 79Lymphoma, T-Cell, Cutaneous 67Carcinoma, Merkel Cell 67Sarcoma 66Pancreatic Neoplasms 59Stomach Neoplasms 58Head and Neck Neoplasms 55Carcinoma, Hepatocellular 54Uterine Cervical Neoplasms 53Urinary Bladder Neoplasms 50Triple Negative Breast Neoplasms 44Esophageal Neoplasms 44Prostatic Neoplasms 43Endometrial Neoplasms 42Carcinoma, Squamous Cell 39Brain Neoplasms 39Carcinoma, Transitional Cell 37Lymphoma 34

Interventions

Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Dermatologic × 1 year × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT06120712 2025-12-23

MIZAR-002

Shanghai Juncell Therapeutics

Phase 1/2 Completed
18 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡